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Abstract
 
In addition to their well characterized role in allergic inflammation, recent data confirm that
mast cells play a more extensive role in a variety of immune responses. However, their contri-
bution to autoimmune and neurologic disease processes has not been investigated. Experimen-
tal allergic encephalomyelitis (EAE) and its human disease counterpart, multiple sclerosis, are
considered to be CD4
 
1
 
 T cell–mediated autoimmune diseases affecting the central nervous sys-
tem. Several lines of indirect evidence suggest that mast cells could also play a role in the patho-
genesis of both the human and murine disease. Using a myelin oligodendrocyte glycoprotein
(MOG)-induced model of acute EAE, we show that mast cell–deficient W/W
 
v
 
 mice exhibit
significantly reduced disease incidence, delayed disease onset, and decreased mean clinical
scores when compared with their wild-type congenic littermates. No differences were ob-
served in MOG-specific T and B cell responses between the two groups, indicating that a glo-
bal T or B cell defect is not present in W/W
 
v
 
 animals. Reconstitution of the mast cell popula-
tion in W/W
 
v
 
 mice restores induction of early and severe disease to wild-type levels,
suggesting that mast cells are critical for the full manifestation of disease. These data provide a
new mechanism for immune destruction in EAE and indicate that mast cells play a broader role
in neurologic inflammation.
Key words: autoimmunity • demyelinating diseases • experimental allergic encephalomyelitis • 
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Introduction
 
 
 
Experimental allergic encephalomyelitis (EAE),
 
1
 
 the proto-
typical rodent model of human multiple sclerosis (MS), is
an autoimmune disease characterized by inflammation in
the central nervous system (CNS) (1–3). Like the human
disease, EAE is associated with an early breach of the
blood–brain barrier, focal perivascular mononuclear cell in-
filtrates, and demyelination leading to paralysis of the ex-
tremities (1). The adoptive transfer of myelin-specific
CD4
 
1
 
 T cells to naive animals passively confers EAE, dem-
onstrating that this cell type is critical in the disease process.
However, it is unclear whether these T cells directly dam-
age the myelin sheath or if they activate other cells for this
function. The underlying cause of increased vascular per-
meability that facilitates the entry of T cells into the CNS is
also unknown. In this study, we asked if mast cells could
influence the T cell response and subsequent EAE disease
course. Mast cells, best known for their role in allergic in-
flammation, are distributed in a variety of anatomical sites,
including the CNS, where they are often found adjacent to
blood vessels and nerves (4–7). In addition, mast cells are an
important source of several mediators, including proteases
and vasoactive amines such as histamine. Mast cells also
produce cytokines that have been implicated in either EAE
disease pathology or protection from disease, such as TNF-
 
a
 
and IL-4, respectively (8–12).
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The idea that mast cells contribute to the pathogenesis of
MS is not a new concept. Over 100 years ago, mast cells
were observed in the CNS plaques of MS patients (13).
Subsequent studies reported a correlation between the
number and/or distribution of mast cells and MS or EAE
pathology (14–16). Sites of inflammatory demyelination are
also sites of mast cell accumulation in the brain and spinal
cord, and the percentage of degranulated mast cells in the
CNS correlates with the clinical onset of disease symptoms
in acute EAE (17). Furthermore, levels of tryptase, a mast
cell–specific proteolytic enzyme, are elevated in the cere-
brospinal fluid in the human disease (18). Mast cell–derived
proteases are capable of degrading myelin (19–21), and my-
elin can directly stimulate mast cell degranulation in vitro
(20). Finally, treatment with mast cell–stabilizing drugs or
with pharmacologic antagonists of mast cell mediators such
as serotonin and histamine was shown to reduce disease se-
verity in human MS and in EAE (22–24). Despite this
wealth of correlative data, a direct role for mast cells in the
pathogenesis of neurologic disorders such as MS has not
been definitively established.
 
Materials and Methods
 
Animals.
 
WBB6/F
 
1
 
-Kit
 
W
 
/Kit
 
Wv
 
 (W/W
 
v
 
) female mice (8–12
wk old) and their female congenic littermates, WBB6/F
 
1
 
-Kit
 
1
 
/
Kit
 
1
 
 (F
 
1
 
1
 
/
 
1
 
), were obtained from The Jackson Laboratory. Both
of these groups result from the cross of WB/ReJ-Kit
 
W/
 
1
 
 
 
3
 
C57BL/6-Kit
 
Wv/
 
1 
 
mice. Animal care was provided according to
protocols approved by the Institutional Animal Care and Use
Committee of Emory University.
 
EAE Disease Induction and Clinical Scoring.
 
EAE induction was
performed according to the protocol of Mendel et al. (25). In
brief, 300 
 
m
 
g of myelin oligodendrocyte glycoprotein (MOG)
 
35–55
 
peptide MEVGWYRSPFSRVVHLYRNGK (Microchemical
Facility, Emory University) was dissolved in 100 
 
m
 
l of PBS and
emulsified in an equal volume of CFA (Difco Labs., Inc.) con-
taining 5 mg/ml of 
 
Mycobacterium tuberculosis
 
 H37 RA (Difco
Labs., Inc.). The emulsion (200 
 
m
 
l) was injected subcutaneously
into the flank on days 0 and 7. Pertussis toxin, 500 ng in 500 
 
m
 
l
of PBS (List Biological Labs.), was administered intravenously
into each tail vein on days 0 and 2. Mice were scored daily ac-
cording to the following clinical scoring system: 0, no clinical dis-
ease; 1, tail flaccidity; 2, hind limb weakness; 3, hind limb paraly-
sis; 4, forelimb paralysis or loss of ability to right from supine; 5,
death.
 
Bone Marrow–derived Mast Cell Differentiation and Reconstitution.
 
Bone marrow was harvested from both femurs of 6–8-wk-old
wild-type F
 
1
 
1
 
/
 
1
 
 female mice and cultured in complete RPMI
media (15% heat-inactivated FBS, 50 U/ml penicillin, 50 
 
m
 
g/ml
streptomycin, 2 mM glutamine, 1 mM sodium pyruvate, and 50
 
m
 
M 2-
 
b
 
-ME) containing 25% WEHI-3B supernatant as an IL-3
source (26). In contrast to some previously described methods for
culturing bone marrow–derived mast cells (BMMCs; reference
27–29), recombinant murine stem cell factor (12.5 ng/ml;
 
 
 
R & D
Systems, Inc.) was also added to the culture during the first 2 wk
as described (30, 31). This addition consistently increased the via-
bility of the cultured cells. BMMCs were used after a minimum
of 4 wk in culture at 
 
.
 
96% purity, as determined by flow cyto-
metric analysis. At time of reconstitution, BMMCs (5 
 
3 
 
10
 
6
 
 in
300 
 
m
 
l) were injected intravenously into groups of five to seven
W/W
 
v
 
 mice. Mice were housed for 10 wk before being sub-
jected to EAE disease induction along with age-matched W/W
 
v
 
and F
 
1
 
1
 
/
 
1
 
 controls.
 
Preparation of Tissue for Histologic Examination.
 
After animals
were killed, brains, spinal columns, and other organs were re-
moved and preserved in 10% neutral buffered formalin. Tissues
were embedded in paraffin, sectioned (5 
 
m
 
m), and stained with
hematoxylin and eosin or Giemsa.
 
Flow Cytometry.
 
BMMCs (10
 
6
 
 cells in 100 
 
m
 
l) were blocked
with antibodies to the Fc
 
g
 
 receptors CD16 and CD32 (PharMin-
gen). Cells were incubated with murine IgE (PharMingen) and
then surface stained with directly conjugated mAbs to murine IgE
(rat anti–mouse–FITC; PharMingen) and c-kit (c-kit–PE; Phar-
Mingen). Flow cytometric analyses for BMMC purity were car-
ried out with the appropriate isotype controls. Cells double posi-
tive for c-kit and Fc
 
e
 
RI were considered mast cells.
 
Determination of Anti-MOG Antibody Levels.
 
Antibody level
analyses were performed by specific ELISA to detect anti-MOG
activity. MOG (0.25 
 
m
 
g/well in 0.1 M NaHC0
 
3
 
, pH 9.6) was
adsorbed onto flat-bottomed microtiter plates overnight at 4
 
8
 
C.
After a blocking step of PBS/0.3% Tween 20/5% nonfat dry
milk, plates were incubated with 1:100 dilutions of mouse sera in
PBS/0.3% Tween 20. Anti-MOG antibodies bound to the
MOG-coated plate were detected using peroxidase-conjugated,
affinity-purified IgG fractions of isotype-specific goat anti–mouse
IgG, IgG1, IgG2a, IgG2b, or IgG3 (PharMingen) diluted 1:1,000
in PBS/0.3% Tween 20. Assays were developed with 3,3
 
9
 
,5,5
 
9
 
-
tetramethylbenzidine peroxidase substrate (KPL), stopped with
H
 
3
 
PO
 
4
 
 (1:20 dilution), and read at a wavelength of 450 nm on a
microplate reader.
 
Statistical Analyses.
 
Statistical analyses were performed using
GraphPad Prism (Software for Science). Group mean clinical
scores were analyzed by paired 
 
t
 
 test for comparison of two
groups. Repeated measures of analysis of variance (ANOVA), fol-
lowed by the Bonferroni post-test, were used for comparison of
the mean clinical scores of the three groups in the reconstitution
experiments. Comparison of group incidence (number of animals
with disease/
 
n
 
) was analyzed by Fisher’s exact test. Survival
curves (animals positive for disease) were plotted according to the
method of Kaplan-Meier, and significance was calculated by the
log-rank test. Mean high scores were compared by student’s 
 
t
 
 test
or ANOVA with Bonferroni post-test for comparison of two or
three groups, respectively.
 
Results
 
W/W
 
v
 
 Mice Show a Delay in Time of Disease Onset and a
Reduction in Disease Severity.
 
To directly evaluate the in
vivo role of mast cells in acute EAE, mast cell–deficient
WBB6/F
 
1
 
-Kit
 
W
 
/Kit
 
Wv
 
 (W/W
 
v
 
) mice and their congenic
wild-type WBB6/F
 
1
 
-Kit
 
1
 
/Kit
 
1
 
 (F
 
1
 
1
 
/
 
1
 
)
 
, 
 
littermates (H-
2
 
bxj
 
) were immunized with the encephalitogenic MOG
 
35–55
 
peptide. MOG can induce typical EAE disease in C57BL/6
mice and other H-2
 
b
 
 strains (25). MOG, which comprises
only 
 
z
 
0.05% of myelin proteins, elicits a major antibody
response that has been correlated with disease severity and
demyelination in both human disease and animal models of
MS (32–34). In three independent experiments, W/W
 
v
 
mice developed significantly less severe disease than wild-
type mice, as indicated by lower daily mean clinical scores
(
 
P
 
 , 
 
0.0001; Fig. 1 A). In addition, mast cell–deficient an- 
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imals also demonstrated a delayed onset and lower inci-
dence of disease when compared with their wild-type
counterparts (
 
P 
 
, 
 
0.0003; Fig. 1 B). Sham-immunized
wild-type (
 
n
 
 5 
 
3) and mast cell–deficient animals (
 
n
 
 5 
 
4)
that received pertussis toxin and adjuvant alone showed no
clinical signs of disease (data not shown). The cumulative
analyses of disease parameters are presented in Table I.
 
Inflammatory Infiltrates Are Present in the CNS of Diseased
Animals.
 
In addition to the clinical changes observed, an-
imals were also examined for histologic evidence of disease
induction. Initially, we confirmed the presence of CNS
mast cells in naive animals used in this model system. Using
metachromatic staining, mast cells were identified in CNS
samples of wild-type mice only, particularly in perivascular
regions of the hippocampus, leptomeninges, habenula, and
thalamus (Fig. 2, A and B). Tissue samples from immunized
wild-type and W/W
 
v
 
 mice were also examined for the
presence of inflammatory lesions. Typical mononuclear in-
filtrates with perivascular cuffing were noted in the brains
and spinal cords of diseased mice in both groups (Fig. 2, C
and D). No apparent differences between the two groups
were observed in the composition or distribution of in-
flammatory infiltrates. Mast cells were not identified in the
inflammatory lesions of wild-type mice, consistent with the
previous findings of Ibrahim et al. (35) in which mast cells
were found in lesions from chronic but not acute disease.
 
Reconstitution of W/W
 
v
 
 Mice with BMMCs Restores EAE
Disease Onset and Severity to Wild-Type Levels.
 
If mast cell
deficiency alone accounts for the differences in EAE disease
parameters observed in W/W
 
v
 
 mice, reconstitution of the
mast cell population in these animals should restore disease
incidence and severity to the level of wild-type animals.
The development of functional mast cells is dependent on
the interaction of stem cell factor (SCF) with its receptor,
c-kit, expressed on bone marrow–derived pluripotent stem
cells. The mast cell deficiency of W/W
 
v
 
 mice is due to
mutations in c-kit that compromise its signaling function
(36, 37). The mast cell population can be reconstituted in
these animals by intravenous injection of c-kit
 
1
 
 bone mar-
row cells or in vitro–differentiated, bone marrow–derived
mast cell precursors (BMMCs) from wild-type animals (4,
27, 29, 38–43). Mast cell numbers in the skin, respiratory
tract, and gastrointestinal tissues of the W/W
 
v
 
 mice after
transplantation with either bone marrow cells or BMMCs
are comparable to those of wild-type animals by 10–12 wk
after transplantation. Importantly, the phenotypic charac-
teristics of these cells resemble the local, native populations
of mast cells in normal mice (29, 38, 39).
We performed mast cell reconstitution in 8–10-wk-old
W/W
 
v
 
 recipients by intravenous injection of BMMCs
(
 
.
 
96% purity, as determined by flow cytometry; Fig. 3) to
Figure 1. W/Wv mice show a delay in disease onset and a reduction in
disease severity. (A) Clinical scores were assigned daily to wild-type (n 5
16) and W/Wv (n 5 17) mice, and the mean of each group was reported
(P , 0.0001 as determined by paired t test). (B) Graph represents the per-
cent of total animals that demonstrated disease by day 30 after immuniza-
tion (P , 0.0003). Curve was plotted according to the method of Kaplan-
Meier, and significance was calculated by the log-rank test. Results in A
and B represent cumulative data from three independent experiments.
 
Table I.
 
Cumulative Analysis of EAE Disease Parameters
 
Group Incidence
 
*
 
Mean day of onset
 
‡
 
Mean high score‡
P , 0.003 P , 0.03§ P , 0.008
Wild-type F1
1/1 15/16 18.0 6 2.65 2.42 6 0.28
W/Wv 7/17 24.3 6 2.96 0.61 6 0.22
*Comparison of group incidence analyzed by Fisher’s exact test.
‡Results are expressed as the mean (6SE). Comparisons analyzed by Student’s t test.
§Only animals positive for disease are included in calculation.816 Essential Role for Mast Cells in Experimental Allergic Encephalomyelitis
repair the mast cell deficit. To assess the establishment of
mast cells in these mice, animals were killed 14–16 wk after
reconstitution, and major organs were examined for the
presence and distribution of mast cells. Mast cells were ob-
served in the gut, CNS, and bone marrow as well as other
organs in distribution patterns consistent with those seen in
wild-type mice (Fig. 4). As expected, no mast cells were de-
tected in tissues obtained from W/Wv mice.
The selectivity of the mast cell reconstitution was con-
firmed by hematocrit (Hct) determination (27, 39–41).
W/Wv mice are anemic (Hct 38.0 6 3.0%) compared with
wild-type F1
1/1 mice (Hct 51.5 6 0.71%). Reconstituted
W/Wv mice remain anemic (Hct 33.6 6 3.1%) after
BMMC transplantation, demonstrating that all hematologic
deficits are not restored by this procedure.
10 wk after reconstitution, BMMC recipients as well as
age-matched wild-type and W/Wv mice were subjected to
the EAE disease induction protocol. As shown in Fig. 5 A, re-
establishment of the mast cell population in W/Wv mice com-
pletely restored the ability of these animals to develop severe
disease. When compared with wild-type mice, the mast cell–
reconstituted animals showed a similar time of onset, daily
Figure 2. Histologic analyses of CNS tissues in WBB6/F1
1/1 mice. After sacrifice of the animals, brains, spinal columns, and other organs were re-
moved and preserved in 10% neutral buffered formalin. Paraffin-embedded tissue sections were stained with Giemsa (A and B) or hematoxylin and eosin
(C and D). (A) Mast cell (arrow) located within the thalamic border region of the habenula; 340. (B) Two mast cells (arrows) located in the habenula.
The third ventricle is also noted (V); 320. Inset, the same two mast cells 340. (C) Multiple inflammatory infiltrates (arrows) found in spinal cord section
of a diseased animal; 310. (D) Focal inflammatory infiltrate found in the brain parenchyma of a diseased animal; 340.
Figure 3. Flow cytometric analysis of the in vitro–differentiated
BMMC population. Cells double positive for c-kit and FceRI were con-
sidered mast cells. Greater than 96% of the population was positive for
both mast cell markers, c-kit (c-kit–PE) and FceRI (IgE 1 rat anti–
mouse–FITC).817 Secor et al.
mean clinical score, and disease incidence (Fig. 5). Inflamma-
tory infiltrates in the brain and spinal cord were also similar
(data not shown). In all disease parameters examined, signifi-
cant differences existed between mast cell–deficient mice and
those with intact mast cell compartments (Fig. 5 and Table II).
In the reconstitution experiments, it was noted that
wild-type and W/Wv animals demonstrated higher mean
clinical scores than those observed in younger animals of
respective genotypes (Fig. 1 A). In addition, some individ-
ual W/Wv mice had clinical scores as high as those of the
wild-type animals. The explanation for these observations
is unclear, but they may be due to age-related differences in
host sensitivity to pertussis toxin or peptide dose. These
possibilities are presently being examined.
Immunized W/Wv Mice Mount Anti-MOG–specific T and
B Cell Responses Similar to Wild-Type F1
1/1 Mice. While
it is formally possible that W/Wv mice have T cell deficits
that could account for the differences in disease parameters
demonstrated between wild-type and mast cell–deficient
animals, we believe this is unlikely. Thymocytes are c-kit1,
and the defect in c-kit carried by W/Wv mice could poten-
tially hinder T cell development in these animals; however,
previous characterizations of W/Wv mice revealed no such
T cell deficits (44, 45). It has also been demonstrated that
IL-7, which has many activities that overlap with SCF, can
direct the development of normal T cells in c-kit–deficient
mice (44). In addition, we evaluated MOG-specific prolif-
erative responses, cytokine profiles, and antibody produc-
tion in both groups. Splenocytes from MOG-immunized
wild-type and W/Wv mice mounted equivalent prolifera-
tive responses and IFN-g cytokine production in response
to in vitro stimulation with MOG peptide (data not
shown). No IL-4 was detected in these assays. Wild-type
and W/Wv mice, as well as BMMC-reconstituted W/Wv
animals, produced similar levels of MOG-specific IgG (Fig.
6). MOG-specific IgG1 and IgG2b subtypes were also de-
tected in all three groups. Interestingly, the MOG-specific
IgG1 levels of W/Wv and BMMC-reconstituted W/Wv
mice were significantly higher (P , 0.05, ANOVA) than
Figure 4. BMMC transplantation reconstitutes mast cell populations in
organs of W/Wv mice. BMMCs were injected intravenously into groups
of five to seven W/Wv mice. Mice were housed for 10 wk before being
subjected to EAE disease induction along with age-matched W/Wv and
wild-type controls. After a 30-d disease course, animals were killed, and
Giemsa-stained sections were obtained from paraffin-embedded organ
samples. (A) Mast cell (arrow) present in the gut of a wild-type F1
1/1
mouse. Arrowhead denotes blood vessel; 340. (B) Mast cells (arrows)
present in the gut of a BMMC-reconstituted W/Wv mouse; 340.
Figure 5. Reconstitution of W/Wv mice with BMMCs restores EAE
disease onset and severity to wild-type levels. (A) Clinical scores were as-
signed daily to wild-type (n 5 10), W/Wv (n 5 8), and W/Wv 1 BM-
MCs (n 5 12) mice, and the mean of each group was reported (P ,
0.0001; post-test results comparing W/Wv to wild-type or W/Wv to re-
constituted group: P , 0.001). Repeated measures of ANOVA followed
by the Bonferroni post-test was used for comparison of the mean clinical
scores of the three groups in the reconstitution experiments. (B) Graph
represents the percent of total animals who demonstrated disease by day
30 after immunization (P , 0.004). Curve was plotted according to the
method of Kaplan-Meier, and significance was calculated by the log-rank
test. Results from A and B represent cumulative data from two indepen-
dent experiments.818 Essential Role for Mast Cells in Experimental Allergic Encephalomyelitis
those of wild-type mice. The biological significance of this
observation is unclear. However, it may indicate that c-kit
signaling pathways play an as yet unidentified role in B cell
isotype switching. Alternatively, the kinetics of IgG1 anti-
body production may be altered in these mutant animals.
Despite these differences in IgG1 levels, it is unlikely that
this has a major effect on the development of EAE, because
wild-type and BMMC-reconstituted mice exhibit similar
disease courses. Also of note, total serum IgE was high in im-
munized animals within all groups, yet MOG-specific IgE
was undetectable (data not shown). These results indicate
that there are no global T or B cell deficits in W/Wv mice.
Taken together with the demonstration that mast cell recon-
stitution with a virtually pure BMMC population restores
disease susceptibility, these data support the hypothesis that it
is the absence of mast cells in the W/Wv animals that predis-
poses them to delayed onset and less severe disease.
Discussion
The data reported in this study provide direct evidence
that mast cells influence both the initiation and the severity
of EAE in vivo, yet many questions regarding mast cell ac-
tivation and effector mechanisms remain to be answered.
Although cross-linkage of the high-affinity IgE receptor
(FceRI) on mast cells is a well characterized pathway of
mast cell activation, there are several alternative pathways
that could be operational in this disease. Ig-dependent
mechanisms may include involvement of anti-MOG anti-
bodies, which have been implicated in both human and ro-
dent forms of the disease (34, 46). Levels of IgG2b in par-
ticular are correlated with disease severity in MOG-induced
EAE in NOD mice (47). Our finding that both IgG1 and
IgG2b are produced in MOG-induced EAE, coupled with
the fact that mast cells express FcgRIIB/III (receptors that
specifically interact with these Ig subtypes; reference 48), is
consistent with the possibility that these antibodies have a
role in FcgR-mediated mast cell activation.
Mast cells can also be directly activated via Ig-indepen-
dent pathways by neuropeptides, such as substance P, cer-
tain complement components, and estradiol, an observa-
tion that may explain the increased susceptibility of females
to MS (49, 50). It was recently shown that activated T lym-
phocytes can induce degranulation and cytokine produc-
tion by human mast cells after cell–cell contact (51, 52).
These data indicate that direct interaction with autoreactive
T cells may be sufficient for mast cell activation.
The site of mast cell activation and influence in this
model of EAE is also unknown. We did not detect mast
cells in the CNS lesions from wild-type or mast cell–recon-
stituted W/Wv mice. This may be due to the difficulty of
detecting degranulated mast cells using classic histologic
stains. Because of the potent activity of mast cell mediators,
very few mast cells may be required to exert profound local
effects. Alternatively, mast cells may act at sites distant from
the site of CNS destruction. Activated mast cells can mi-
grate to local lymph nodes (53), indicating their potential
to influence naive T cell activation and differentiation.
Once mast cell activation occurs, the release of numerous
mast cell mediators could act at several levels to influence
disease induction and/or progression. For example, alter-
ation of the blood–brain barrier through release of vasoac-
tive amines may facilitate entry of autoreactive T cells into
the CNS (54–56). Proinflammatory cytokines such as
Table II. Cumulative Analysis of EAE Disease Parameters in BMMC Reconstitution Experiments
Group Incidence* Mean day of onset‡ Mean high score‡
P , 0.03 P , 0.008§ P , 0.002
Wild-type F1
1/1 10/10 12.4 6 0.64¶ 3.45 6 0.31¶
W/Wv 4/8 18.0 6 2.64 1.63 6 0.65
W/Wv 1 BMMC 12/12 13.1 6 0.67i 3.75 6 0.17¶
*Comparison of group incidence analyzed by Fisher’s exact test.
‡Results are expressed as the mean (6SE). 
§Only animals positive for disease are included in calculation.
iP , 0.05 or ¶P , 0.01 comparing wild-type or reconstituted group versus W/Wv as determined by Bonferroni ANOVA post-test analyses.
Figure 6. Detection of MOG-specific IgG and IgG subclasses. Upon
sacrifice, serum was obtained from wild-type (n 5 16), W/Wv (n 5 16),
and BMMC-reconstituted W/Wv (n 5 10) mice and analyzed for MOG-
specific isotype and IgG subclass levels by ELISA. Results represent cu-
mulative data from four experiments.819 Secor et al.
TNF-a could regulate endothelial expression of adhesion
molecules, kill myelin-producing cells, and degrade myelin
components (57, 58). TNF-a has also been shown to pro-
mote local presentation of autoantigen in the diabetic
model of NOD mice (59). Mast cell proteases may directly
damage the myelin sheath and adjacent nerves (19, 21, 22).
Finally, regulatory cytokines such as IL-4 and IL-10 could
influence the development of an autoimmune T cell re-
sponse or modulate an ongoing response both in the pe-
riphery and within the CNS (60, 61).
Until recently, the contribution of mast cells to nonspe-
cific and specific inflammatory processes was virtually ig-
nored outside the realm of allergy research. It is becoming
increasingly clear that mast cells can provide protection in
bacterial infections (27, 42). Through their ability to regu-
late a myriad of both adaptive and innate immune re-
sponses, mast cells may play a major role in many immune-
mediated diseases as well. The demonstration that mast cells
are significant effector cells in EAE alters the way we have
classically thought about this disease in humans. These data
pave the way for completely new avenues of immunother-
apy that could complement treatment regimens based
solely on altering the autoreactive T cell response.
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